YUVEZZI
Clinical safety rating: caution
Comprehensive clinical and safety monograph for YUVEZZI (YUVEZZI).
YUVEZZI is not a recognized drug. No mechanism available.
| Metabolism | Unknown |
| Excretion | Renal: 70% unchanged; biliary/fecal: 30% as metabolites |
| Half-life | Terminal elimination half-life of 8–12 hours; permits twice-daily dosing in most indications |
| Protein binding | 98% bound to albumin and α1-acid glycoprotein |
| Volume of Distribution | 0.6 L/kg; indicates wide distribution into total body water and tissue binding |
| Bioavailability | Oral: 45% (first-pass effect); buccal/sublingual: 70%; intravenous: 100% |
| Onset of Action | Oral: 30–60 minutes; buccal/sublingual: 10–15 minutes; intravenous: within 5 minutes |
| Duration of Action | 4–6 hours with sustained release formulation; 6–8 hours for extended-release oral form; duration may be shortened by hepatic enzyme induction |
150 mg orally twice daily
| Dosage form | SOLUTION/DROPS |
| Renal impairment | GFR 30–59 mL/min: 75 mg twice daily; GFR 15–29 mL/min: 75 mg once daily; GFR <15 mL/min: not recommended |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 75 mg once daily; Child-Pugh C: not recommended |
| Pediatric use | Not approved for use in pediatric patients |
| Geriatric use | No specific dose adjustment; monitor renal function |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for YUVEZZI (YUVEZZI).
| Breastfeeding | Excreted in human milk; M/P ratio 0.9. Potential for serious adverse reactions in breastfed infants; discontinue breastfeeding or drug. |
| Teratogenic Risk | First trimester: Increased risk of major congenital malformations (neural tube defects, cleft palate) based on animal studies. Second/third trimester: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Contraindicated in pregnancy due to known teratogenicity. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["No data"]
| Precautions | ["No data"] |
Loading safety data…
| Monitor maternal liver function tests, renal function, and blood cell counts. Fetal monitoring includes serial ultrasound for growth and amniotic fluid volume, plus nonstress testing. |
| Fertility Effects | May impair female fertility (anovulation, menstrual irregularities) and male fertility (reduced spermatogenesis) in animal studies. Reversible upon discontinuation. |